AC Immune’s Diagnostic Achieves FDA Fast Track Status

AC Immune SA (ACIU) has released an update.

AC Immune SA’s Tau-PET diagnostic, PI-2620, has been granted Fast Track Designation by the FDA for Phase 3 trials in Alzheimer’s, progressive supranuclear palsy, and corticobasal degeneration. This milestone highlights the potential of PI-2620 to improve early and precise diagnosis of neurodegenerative diseases, which is crucial for effective treatments. The designation reinforces AC Immune’s position at the forefront of neurodegenerative disease management and follows previous Fast Track recognitions for their active immunotherapies.

For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.